Synthetic peptides representing amino acids 156 to 170 of virus capsid protein VP2 from human rhinovirus (HRV) type 2 have previously been used to elicit a neutralizing antibody response; polyclonal antisera against this peptide have been compared with a virusneutralizing monoclonal antibody (8F5) which recognizes the same linear sequence. The neutralizing activity of both antibodies against virus is abolished by an amino acid substitution in VP2 at position 163 but only the peptide antiserum neutralizing activity is affected by a change in VP2 at position 158. The minimal binding site of 8F5 has been mapped, using overlapping peptides, to a sequence TRLNPD covering VP2 residues 160 to 165. Using affinity purification it has been shown that 8 to 10% of total neutralizing activity of polyclonal rabbit or guinea-pig antivirus antiserum is due to recognition of this linear VP2 156 to 170 determinant. Furthermore, a similar population of neutralizing antibodies appears to be associated with an immune response to recent HRV infection in humans. These results confirm the existence of linear determinants on the surface of HRV which may be mimicked by suitable synthetic peptides.
Synthetic peptides representing amino acids 156 to 170 of virus capsid protein VP2 from human rhinovirus (HRV) type 2 have previously been used to elicit a neutralizing antibody response; polyclonal antisera against this peptide have been compared with a virusneutralizing monoclonal antibody (8F5) which recognizes the same linear sequence. The neutralizing activity of both antibodies against virus is abolished by an amino acid substitution in VP2 at position 163 but only the peptide antiserum neutralizing activity is affected by a change in VP2 at position 158. The minimal binding site of 8F5 has been mapped, using overlapping peptides, to a sequence TRLNPD covering VP2 residues 160 to 165. Using affinity purification it has been shown that 8 to 10% of total neutralizing activity of polyclonal rabbit or guinea-pig antivirus antiserum is due to recognition of this linear VP2 156 to 170 determinant. Furthermore, a similar population of neutralizing antibodies appears to be associated with an immune response to recent HRV infection in humans. These results confirm the existence of linear determinants on the surface of HRV which may be mimicked by suitable synthetic peptides.
The human rhinovirus (HRV), identified as the major causative agent of the common cold (Stott & Killington, 1972) , is a member of the picornavirus family. The icosahedral protein capsid, which contains the positivestrand genomic RNA, consists of 60 protein trimers made up of three surface structural proteins, VP1, VP2 and VP3 (Mendappa et al., 1971 ; Rueckert, 1976) , with a fourth protein, VP4, located internally. Four major antigenic sites have been identified on the surface proteins of the HRV-14 virion using monoclonal antibody (MAb) escape mutants (Sherry et al., 1986) . These are referred to as NIm Ia, NIm Ib, NIm II and NIm III, according to the viral protein on which they are principally located. Sites corresponding to, but significantly different from, NIm Ia and NIm II also appear on human rhinovirus serotype 2 (HRV-2) (Appleyard et al., 1990) . Synthetic peptides representing linear portions of the protein sequence of HRV-2 have previously been shown to be recognized by antisera raised against HRV-2 (Francis et al., 1987a) . One of these peptides representing part of the NIm II antigenic site from amino acids 156 to 170 of VP2 (VKAETRLNPDLQPTE), which appears as a 'puff' on the virus surface between flEl and fiE2 (Rossmann et al., 1985) , was used to raise peptidespecific antisera which bound and neutralized native virus (Francis et al., 1987a) . A neutralizing mouse MAb, designated 8F5, produced against HRV-2 has also been identified as binding to VP2 at a site that includes part of the amino acid sequence covered by the synthetic peptide (Skern et al., 1987) .
The specificities of MAb 8F5 and of a rabbit antipeptide antiserum produced to keyhole limpet haemocyanin (KLH)-coupled synthetic NIm II peptide were investigated by indirect ELISA, in which peptide was bound to the solid phase and the specific antibodies were detected using enzyme-labelled antispecies antibody (Table 1) . Both samples had high titres against the HRV-2 peptide and to a peptide containing a single amino acid change (Ala to Thr) at position 158, which is known to occur in a laboratory variant of HRV-2, HRV2 Wellcome (Appleyard et al., 1990) . The MAb and the peptide antiserum did not recognize an analogous NIm II peptide taken from another serotype of rhinovirus, HRV-14, or peptides representing the 20 C-terminal residues of VP1 or VP2 from HRV-2.
The peptide antiserum and the antivirus MAb were shown to recognize HRV-2 in both ELISA and radioimmunoassay (Table 2 ). Both samples had higher ELISA titres against purified virus coated directly onto the solid phase than they did against virus captured using a specific anti-HRV-2 antibody. This can be explained by the fact that virus particles become distorted when bound to an ELISA plate (McCullough et al., 1985) , exposing antigenic sites not normally accessible to antipeptide antibodies (Francis et al., 1987b Anti-HRV-2 VP2 peptide 156 to 170 polyclonal 4.6* 4-6 < 1 < 1 < 1 Anti-HRV-2 MAb 8F5 4.0 4.0 < 1 < 1 < 1 * Endpoint titres expressed as log~o dilution of antiserum. (Table 3) ; the residues TRLNPD (amino acids 160 to 165) were shown to be an important part of the epitope. Although MAb 8F5 could bind to and neutralize virus with an Ala to Thr substitution at amino acid 158 of VP2, MAbselected mutants of HRV-2 Wellcome, 822R4 and 822R5 (Appleyard et al., 1990) , were resistant to neutralization. These contain amino acid changes, Asn to Tyr and Asn to Ser at position 163 of VP2 respectively, within the proposed binding site for the antivirus MAb. The polyclonal peptide antisera also failed to neutralize these two mutants, indicating that the Asn residue may also be important for binding of antipeptide 156 to 170 antibodies ( Table 2 ). The demonstration that neutralizing antivirus antiserum recognized peptide 156 to 170 (Francis et al., 1987a) implied that a population of antibodies existed within the antiserum which was capable of interacting with that region of the virus particle. To investigate the virus-binding and neutralizing activity of such a population of antibodies, they were separated from the serum by affinity purification. This was achieved using a column of aminohexyl Sepharose-4B beads to which peptide 156 to 170 was coupled with glutaraldehyde (Cambiaso et al., 1975) . Aliquots (1 ml) of polyclonal virus antisera, taken from one rabbit 56 days postimmunization with I Ixg of HRV-2, and from two guineapigs, one with high antipeptide 156 to 170 activity (gp 1) and one with low antipeptide 156 to 170 activity (gp 2), 84 days after being inoculated on day 0 and day 56 with 0.2 txg of purified HRV-2, were recycled through the column. Non-specific proteins and antibodies, forming the unbound fraction (peak 1) were then washed through with phosphate-buffered saline pH 7.2 and the peptidespecific bound antibodies (peak 2) were eluted with 0-1 M-glycine-HC1 pH 3.0. These fractions were restored to normal pH using 1 M-NaHCO3 and the active fractions, measured by indirect ELISA against peptide and/or virus, were pooled and concentrated to the original volume of the serum sample (data not shown). The efficiency of the column was confirmed by rerunning the eluted peak 2 through the column and demonstrating that all the antibody had bound. Separation of the peptide-specific antibodies in the rabbit antiserum and one of the guinea-pig antisera (gp 1) was shown to be successful by indirect ELISA (Table 4 ). The first peak of non-specific antibodies was negative against peptide whereas the second peak was positive. The affinitypurified antibodies also recognized HRV-2 in indirect and capture ELISA. However, the second guinea-pig antiserum (gp 2), included in this study because it had previously been shown to neutralize virus but demonstrated no antipeptide 156 to 170 activity by ELISA, yielded a peak of peptide-specific antibodies from the column which gave a low ELISA titre with peptide 156 to 170 but which recognized virus at titres similar to those of the other affinity-purified serum samples. The peptide-reactive antibodies present in the serum of gp 2 may have recognized a conformation(s) of the peptide which was available on the column but not when the peptide was bound to an ELISA plate. The whole antiserum and the affinity-purified antibodies were also assayed for their neutralization activities against HRV-2 and HRV-2 Wellcome (Table 4) in duplicate assays using twofold dilutions of antisera against 100 TCID50 virus. All three antisera produced high titres of neutralization against both viruses, with the rabbit serum maintaining 2.7 2-9 3.6 1-9 1-5 Guinea-pig (gpl) polyclonal serum 4.0 4.8 4.6 3.1 2-9 Peak 1 < 1 4.5 4.5 3.1 2.8 Peak 2 3.7 3-9 3-6 2.1 1.6 Guinea-pig (gp2) polyclonal serum < 1 5-0 4-0 3-t 2-8 Peak 1 < 1 5.0 4-8 3.1 2.6 Peak 2 1-2 3.4 3-3 2.1 1.5 * logio dilution giving endpoint titre. t loglo SNso against 100 TCIDso. Pre-serum (B.S.) < 1-2 < 1-2 Pre-serum (B.S.) peak 1 < 1-2 < 1.2 Pre-serum (B.S.) peak 2 < 1.2 < 1.2 Post-serum (B.S.)
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the same titres against HRV-2 Wellcome. The reduction in titre seen with guinea-pig polyclonal (0.2 to 0.3 lOgl0) and peak 1 (0-3 to 0-5 log10) antisera against HRV-2 Wellcome may be due to a higher proportion of conformational NIm II-like antibodies which were not removed on the peptide column. Such MAbs against HRV-2 have been described (Appleyard et al., 1990) . However, the peptide affinity-purified antibodies from the three antivirus antisera all had reduced titres (0.4 to 0-6 lOgl0) against variant virus HRV-2 Wellcome. Thus the peptide 156 to 170-reactive antibody population in antivirus antisera and antipeptide antisera appears to discriminate similarly between viruses with Ala or Thr at position 158 of VP2 (Table 3) . Moreover, comparing the titres of the affinity-purified antibodies to those of the original antisera, the peptide-reactive antibodies represent 8 to 10% of the total neutralizing activity of the polyclonal antisera, indicating that the peptide 156 to 170 site is an important linear antigenic and immunogenic site on HRV for the production of neutralizing antibodies.
To investigate whether a similar population of peptide-reactive and virus-neutralizing antibodies are produced in response to a natural infection with HRV, serum samples (800 gl) taken from a human volunteer (B.S.) pre-and post-infection with HRV-2 were passed through the peptide affinity column. Unfortunately, both the pre-and post-infection samples gave high antivirus titres by ELISA and no antipeptide 156 to 170 reactivity, similar to the results obtained previously with gp 2 antiserum (data not shown). However, monitoring of the fractions at 280 nm revealed that a small protein peak of affinity-purified antibodies had been eluted from the column with both of the serum samples. This peak and the non-adsorbed protein peak were concentrated to 800 ~tl and assayed along with the original serum samples for their ability to neutralize both HRV-2 and HRV-2 Wellcome (Table 5) . No neutralization of either of the viruses was obtained with pre-infection samples, whereas the post-infection serum and its two component fractions of non-specific and peptide 156 to 170-specific antibodies neutralized both of the viruses. Pre-infection samples from two other volunteers (M.E. and E.B.) gave higher neutralization titres than the post-infection serum described above but the small peak of eluted peptidespecific antibodies had no neutralizing activity. These two individuals did not develop the symptoms of a cold upon virus challenge whereas the previous individual (B.S.) did (W. S. Barclay, personal communication). This could imply that the neutralizing antibodies produced towards VP2 region 156 to 170 were produced in response to recent infection with HRV-2, whereas this population was not significant in the serum of individuals with long term pre-existing HRV-2-reactive antibodies.
In conclusion, we have demonstrated that antibodies exhibiting specificity for a viral epitope represented by a linear sequence of amino acids from VP2 bind to, and neutralize, HRV. Moreover, a significant proportion of these antibodies are produced during an immune response to the virus, both experimentally in animals and during the course of a recent infection in humans. These results support the use of a linear peptide representing the HRV VP2 region 156 to 170 in the development of a synthetic peptide vaccine against this major causative agent of the common cold.
